On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) announced that it will launch the first phase of consultations on new guidelines. The first phase will include a policy roundtable with stakeholders on December 5 (English) and December 6 (French), at which stakeholders will be invited to share their views on certain themes, including:
- efficient monitoring of prices without price setting,
- transition to PMPRB11 – new versus existing medicines,
- price reviews during product life cycle, and
- investigations and referral to hearing.
A scoping paper, to be published in advance of the roundtable, will include details regarding participation and specific questions for feedback.
As previously reported, the PMPRB’s consultation will be conducted in two stages, the roundtable first, and the second (in 2024) will focus on the development of new guidelines.
Separately, in October, the Minister of Health announced the appointment of Peter Moreland-Giraldeau and Dr. Emily A. Reynen to the PMPRB.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Minister of Health proposes legislation for first phase of national universal pharmacare
On February 29, 2024, the Minister of Health announced the introduction of Bill C-64, An Act respecting pharmacare (Pharmacare Act).Read More -
PMPRB releases 2022 Annual Report and March 2024 NEWSletter
On February 16, 2024, the Minister of Health tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB).Read More